Quralis Corp.

Address: 35 Cambridge Park Drive

Sponsor Overview

assignment

Specializations

Amyotrophic Lateral Sclerosis and Motor Neuron Disorders

Quralis Corp. focuses on clinical research in amyotrophic lateral sclerosis, including studies in people living with ALS and closely related disease entries recorded under the same condition. The sponsor’s work is centered on therapeutic development for motor neuron disease and associated neurological impairment.

Amyotrophic lateral sclerosis
Motor neuron disease
Neurological degeneration

Research activity in this area includes evaluation of treatments intended for patients with progressive neuromuscular weakness and loss of motor function.

Epilepsy and Neural Excitability

The sponsor also supports clinical research in epilepsy and conditions linked to abnormal nerve signaling, reflecting interest in disorders of neuronal excitability and seizure-related therapeutic targets.

Epilepsy
Neuronal excitability
Seizure disorders

This area connects broader neurological investigation with therapies aimed at stabilizing disrupted electrical activity in the nervous system.

Neuropathy and Peripheral Nerve Function

Quralis Corp. funds studies relevant to neuropathy and hyperexcitability nerve disorder, indicating a therapeutic interest in peripheral nerve sensitivity, abnormal nerve firing, and symptom patterns associated with nerve dysfunction.

Neuropathy
Hyperexcitability nerve disorder
Peripheral nerve function

These research efforts address neurological conditions involving sensory disturbance and altered nerve responsiveness.

Healthy Volunteer Pharmacology

Several studies are conducted in healthy participants, showing a strong interest in early clinical evaluation of pharmacokinetics, tolerability, and formulation characteristics for neurological therapies. This work supports characterization of how candidate medicines behave in the body before disease-focused use.

Healthy participants
Pharmacokinetics
Tolerability

These investigations are aligned with development of compounds intended for central and peripheral nervous system disorders.

Sponsored Trials

Trial Name	Country	Status
A Safety and Tolerability Study of QRL-101 in Healthy Participants	The Netherlands	Recruiting
Evaluation of the Effects of a Novel Pharmacological Agent on Nerve Sensitivity in Healthy Volunteers with Hyperexcitability Nerve Disorder	The Netherlands	Not Recruiting
Pharmacokinetic and Pharmacodynamic Evaluation of QRL-101 in a Randomized, Placebo-Controlled, Double-Blind, Single Dose Phase 1 Study in Amyotrophic Lateral Sclerosis Patients	The Netherlands	Not Recruiting
Pharmacokinetic Evaluation of QRL-101 Formulations in Healthy Subjects for Amyotrophic Lateral Sclerosis (ALS)	The Netherlands	Not Recruiting
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study on Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Volunteers	The Netherlands	Not Recruiting
Safety and Tolerability Evaluation of QRL-201 in Patients with Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study	Belgium Germany Ireland The Netherlands	Not Recruiting